1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Eli Lilly and Company

Eli Lilly and Company

LLY
Eli Lilly and CompanyUS flagNew York Stock Exchange
1,184.47
USD
-24.53
- -
1.12TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.64
89.09
Basic EPS, GAAP
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23
29.87
Free Cash Flow per Basic Share
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.65
15.16
Dividend per Share
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6
6.47
Book Value per Share
15.79
13.84
13.18
12.72
10.54
9.3
2.72
5.9
9.42
11.21
11.98
15.81
29.65
38
Tangible Book Value per Share
11.91
9.66
4.97
5.16
2.9
7
-8.03
-5.83
-2.73
-0.66
-1.19
2.51
15.77
7.76
Basic Weighted Avg Shares
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
897
894
Sales/Revenue/Turnover
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
79,666
Operating Margin (%)
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
49.72
Depreciation Expense
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,522
1,527
1,767
1,997
2,099
Net Income, GAAP
4,685
2,390
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
26,711
Effective Tax Rate (%)
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
20.49
Profit Margin (%)
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
33.53
Working Capital
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,980
3,400
896
-1,566
4,364
20,401
16,931
LT Debt
4,200
5,333
7,972
8,368
9,940
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
47,858
Total Equity
17,641
15,388
14,590
14,080
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
33,879
Return on Invested Capital (%)
19.52
10.88
12.97
12.59
-0.6
20.9
25.67
29.05
28.27
28.34
25.98
33.89
40.74
40.9
Return on Capital (%)
22.3
10.85
11.08
12.3
-0.86
14.79
44.21
32.16
24.31
24.69
17.84
26.76
35.3
36.53
Return on Common Equity (%)
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
150.18
76.35
63.63
48.92
84.84
101.36
102.44

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,635
4,000
7,050
LT Borrowings
40,868
39,370
47,858
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
895
894
892
Market Capitalization
961,624
821,814
1,069,292

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55,629
54,835
64,672
Cash, Cash Equivalents & STI
7,268
5,282
8,950
Accounts Receivable, Net
17,760
18,429
20,083
Inventories
13,744
14,529
16,793
Total Current Liabilities
35,228
36,634
47,741
Payables & Accruals
22,761
22,576
27,234
ST Debt
1,635
4,000
7,050
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
22,974
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.22
7.42
23
2026
8.28
7.96
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6
2026
1.73
1.73
- -
- -
- -

Company Description

APIChatGPT
CEO
David A. Ricks
Full Time Employees
50,000
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Lilly Corporate Center Indianapolis IN United States of America 46285
IPO Date
Jun 1, 1972
CIK
0000059478
Website
lilly.com
Similar Companies
Bristol-Myers Squibb Company (0R1F.L)
JCR Pharmaceuticals Co., Ltd. (4552.T)
Merck & Co., Inc. (0QAH.L)
Orion Oyj (ORNAV.HE)
Shandong Jintai Group Co., Ltd. (600385.SS)
Grifols, S.A. (GRF.MC)
Business

Company News

APIChatGPT

  • zacks.com

    3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold

  • fool.com

    Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

  • fool.com

    Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?

  • reuters.com

    Novo CEO says obesity market won't be winner-take-all battle with Lilly

  • cnbc.com

    Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'

  • seekingalpha.com

    I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)

  • marketwatch.com

    Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide

  • wsj.com

    Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs

  • reuters.com

    Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

  • prnewswire.com

    Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

  • 247wallst.com

    Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run

  • fool.com

    Why Eli Lilly Topped the Market Today

  • 247wallst.com

    3 Beaten-Down Healthcare Stocks to Buy in August

  • barrons.com

    Nvidia, Eli Lilly, and Disney Show It's Time to Back the Top Dogs

  • marketbeat.com

    Eli Lilly and Company Q2 Earnings Call Highlights

  • fool.com

    Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

  • seekingalpha.com

    Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion

  • etftrends.com

    Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flows

  • seekingalpha.com

    Eli Lilly: Fine Q2 2026 Results, But Alertness Required

  • 247wallst.com

    This Will be Eli Lilly's Price in 2027 And Morgan Stanley Agrees